LifeMD Shares Soar 5.67% on Novo Nordisk Partnership

LifeMD (LFMD) shares surged 5.67% intraday, reaching their highest level since May 2024, with a 0.57% increase in the overall trading session.

The strategy of buying LFMD shares after they reached a recent high and holding for 1 week yielded moderate returns over the past 5 years, with a 7.76% annualized return and a 37.07% overall return. However, the strategy underperformed the market, as evidenced by the 14.87% annualized return and 60.68% overall return of the S&P 500 index over the same period. The LFMD portfolio showed higher volatility compared to the market, with a maximum drawdown of 34.42% versus 12.97% for the S&P 500. This indicates that while there were periods of strong performance, the strategy also faced significant volatility and market fluctuations. Overall, the strategy provided decent returns but came with higher risk compared to a market-based approach.

LifeMD's recent stock surge can be attributed to several key developments. Notably, Novo Nordisk's plan to sell Wegovy through telehealth operators has positively impacted LifeMD's stock price. This strategic move aligns with LifeMD's business model, potentially driving increased demand for their telehealth services.

Additionally, technical analysis from May 19, 2025, suggests a buy signal for LFMD near 7.65 with a stop loss at 7.63. This indicates strong support levels and reflects current trading strategies and market sentiment, further bolstering investor confidence in the stock.

These factors, including strategic partnerships and technical indicators, are influencing LifeMD's stock performance, making it a stock to watch in the coming weeks.